Dianthus Therapeutics, Inc. (DNTH)
88.51
-3.30
(-3.59%)
USD |
NASDAQ |
Nov 16, 14:12
Dianthus Therapeutics Gross Profit Margin (Quarterly) : 90.99% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 90.99% |
| June 30, 2026 | 85.94% |
| March 31, 2026 | 83.59% |
| December 31, 2025 | 65.85% |
| September 30, 2025 | 75.00% |
| June 30, 2025 | 48.70% |
| March 31, 2025 | 88.56% |
| December 31, 2024 | 94.12% |
| September 30, 2024 | 94.66% |
| Date | Value |
|---|---|
| June 30, 2024 | 94.04% |
| March 31, 2024 | 87.76% |
| December 31, 2023 | 77.46% |
| September 30, 2023 | 97.94% |
| June 30, 2023 | 91.33% |
| March 31, 2023 | 82.98% |
| December 31, 2022 | 95.83% |
| September 30, 2022 | -103.2% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Xencor, Inc. | 98.08% |
| ACADIA Pharmaceuticals, Inc. | 89.75% |
| Alnylam Pharmaceuticals, Inc. | 75.19% |
| Anika Therapeutics, Inc. | 61.57% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -21.71% |
| Return on Assets | -20.86% |
| Return on Invested Capital | -21.68% |
| Profit Margin (Quarterly) | -3.85K% |
| Operating Margin (Quarterly) | -4.83K% |
| Return on Net Operating Assets | -1.63K% |